Work

Clinical Studies in Patients with Solid Tumors using a Second‐Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I

Year: 2003

Type: article

Study design: Clinical Trial

Source: Annals of the New York Academy of Sciences

DOI: 10.1196/annals.1281.028

Authors: S. MANI, S. GOEL, M. NESTEROVA, R. M. MARTIN, J. M. GRINDEL, M. L. ROTHENBERG, R. ZHANG, G. TORTORA, Y. S. CHO‐CHUNG

Institutions: Albert Einstein College of Medicine, National Institutes of Health, National Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Alabama at Birmingham, University of Naples Federico II

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: G5797786972, Cancer Center Support Grant

OpenAlex ID: W2052824769

FWCI: 1.494

Cites: 34

Cited by: 31

Related to: 10